Hu Lulu, Jiang Ke, Ding Chan, Meng Songshu
Institute of Cancer Stem Cell, Dalian Medical University Cancer Center, 9Lvshun Road South, Dalian 116044, China.
Department of Avian Infectious Diseases, Shanghai Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Shanghai 200000, China.
Biomedicines. 2017 Jan 11;5(1):5. doi: 10.3390/biomedicines5010005.
Oncolytic viruses (OVs) are capable of exerting anti-cancer effects by a variety of mechanisms, including immune-mediated tumor cell death, highlighting their potential use in immunotherapy. Several adaptation mechanisms such as autophagy contribute to OV-mediated anti-tumor properties. Autophagy regulates immunogenic signaling during cancer therapy which can be utilized to design therapeutic combinations using approaches that either induce or block autophagy to potentiate the therapeutic efficacy of OVs. In this article, we review the complicated interplay between autophagy, cancer, immunity, and OV, summarize recent progress in the contribution of OV-perturbed autophagy to oncolytic immunity, and discuss the challenges in targeting autophagy to enhance oncolytic immunotherapy.
溶瘤病毒(OVs)能够通过多种机制发挥抗癌作用,包括免疫介导的肿瘤细胞死亡,这凸显了它们在免疫治疗中的潜在用途。自噬等几种适应机制有助于OV介导的抗肿瘤特性。自噬在癌症治疗过程中调节免疫原性信号传导,可利用这一点设计治疗组合,采用诱导或阻断自噬的方法来增强OV的治疗效果。在本文中,我们综述了自噬、癌症、免疫和OV之间复杂的相互作用,总结了OV干扰自噬对溶瘤免疫作用的最新进展,并讨论了靶向自噬以增强溶瘤免疫治疗所面临的挑战。